/NVRO
NVRO Stock - Nevro Corp.
Healthcare|Medical - DevicesNYSE
$5.84+0.00%
+$0.00 (+0.00%) • Apr 2
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.61
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.87
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+502.7%upside
Target: $35.20
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NVRO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.78 – $5.90
TARGET (TP)$35.20
STOP LOSS$5.37
RISK/REWARD1:62.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.82
52W High$13.30
52W Low$3.17
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $408.52M | $425.17M | $406.37M | $386.90M | $362.05M |
| Gross Profit | $269.53M | $290.06M | $276.37M | $266.04M | $249.90M |
| Gross Margin | 66.0% | 68.2% | 68.0% | 68.8% | 69.0% |
| Operating Income | $-126,229,000 | $-99,308,000 | $-98,836,000 | $-90,934,000 | $-62,852,000 |
| Net Income | $-113,439,000 | $-92,213,000 | $3.00M | $-131,360,000 | $-83,065,000 |
| Net Margin | -27.8% | -21.7% | 0.7% | -34.0% | -22.9% |
| EPS | $-3.06 | $-2.56 | $0.09 | $-3.77 | $-2.47 |
Company Overview
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
25%
Hold / Neutral
9
56%
Sell / Underperform
3
19%
Analyst Consensus🔴 Bearish
4 Bullish12 Neutral/Bearish
Price Targets
$33
Average Target
↑ 469.5% Upside
Now
$4
Low
$33
Average
$80
High
Based on 20 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 10th 2025 | Jefferies | Upgrade | Hold | $5.85← $4.5 |
| February 7th 2025 | Piper Sandler | Upgrade | Overweight | $5.85← $6 |
| December 3rd 2024 | Wells Fargo | Initiation | Equal Weight | $5 |
| December 2nd 2024 | Morgan Stanley | Downgrade | Underweight | $4← $9 |
| August 9th 2024 | Citigroup | Upgrade | Neutral | - |
| August 8th 2024 | Wolfe Research | Upgrade | Peer Perform | - |
| August 7th 2024 | JMP Securities | Downgrade | Market Perform | - |
| August 7th 2024 | JP Morgan | Downgrade | Underweight | - |
| August 7th 2024 | Wells Fargo | Downgrade | Underweight | $5.5← $13 |
| May 22nd 2024 | Citigroup | Downgrade | Sell | $9← $13.5 |
| February 22nd 2024 | Oppenheimer | Downgrade | Perform | - |
| January 12th 2024 | RBC Capital Mkts | Downgrade | Sector Perform | $20← $23 |
| December 21st 2023 | Canaccord Genuity | Downgrade | Hold | $23 |
| July 19th 2023 | Robert W. Baird | Initiation | Neutral | $26 |
| May 31st 2023 | RBC Capital Mkts | Initiation | Outperform | $40 |
Earnings History & Surprises
NVROBeat Rate
78%
Last 18 quarters
Avg Surprise
+17.4%
EPS vs Estimate
Beats / Misses
14/3
1 met exactly
Latest EPS
$-0.70
Q2 2025
EPS Surprise History
Q3 23
-1.5%
$-0.69vs$-0.68
Q4 23
+15.6%
$-0.65vs$-0.77
Q1 24
+70.0%
$-0.15vs$-0.50
Q2 24
+31.4%
$-0.70vs$-1.02
Q3 24
+31.7%
$-0.43vs$-0.63
Q4 24
+37.8%
$-0.51vs$-0.82
Q1 25
+19.0%
$-0.64vs$-0.79
Q2 25
+23.1%
$-0.70vs$-0.91
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 10, 2025 | — | — | — | — |
Q3 2025 | Aug 4, 2025 | — | — | — | — |
Q2 2025 | May 6, 2025 | $-0.91 | $-0.70 | +23.1% | ✓ BEAT |
Q1 2025 | Mar 4, 2025 | $-0.79 | $-0.64 | +19.0% | ✓ BEAT |
Q4 2024 | Nov 11, 2024 | $-0.82 | $-0.51 | +37.8% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.63 | $-0.43 | +31.7% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-1.02 | $-0.70 | +31.4% | ✓ BEAT |
Q1 2024 | Feb 21, 2024 | $-0.50 | $-0.15 | +70.0% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $-0.77 | $-0.65 | +15.6% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $-0.68 | $-0.69 | -1.5% | ✗ MISS |
Q2 2023 | Apr 26, 2023 | $-1.06 | $-0.98 | +7.5% | ✓ BEAT |
Q1 2023 | Feb 16, 2023 | $-0.49 | $-0.54 | -10.2% | ✗ MISS |
Q4 2022 | Nov 2, 2022 | $-0.71 | $-0.62 | +12.7% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.81 | $-0.71 | +12.3% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-1.11 | $-0.98 | +11.7% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $-0.86 | $-0.86 | 0.0% | = MET |
Q4 2021 | Nov 8, 2021 | $-0.86 | $-0.87 | -1.2% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.71 | $-0.62 | +12.7% | ✓ BEAT |
Q2 2021 | May 5, 2021 | $-0.86 | $-0.85 | +1.2% | ✓ BEAT |
Q1 2021 | Feb 24, 2021 | $-0.35 | $-0.21 | +40.0% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about NVRO
What is NVRO's current stock price?
Nevro Corp. (NVRO) is currently trading at $5.84 per share. The stock has moved +0.00% today.
What is the analyst price target for NVRO?
The average analyst price target for NVRO is $35.20, based on 1 analyst.
What sector is Nevro Corp. in?
Nevro Corp. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NYSE exchange.
What is NVRO's market cap?
Nevro Corp. has a market capitalization of $0.22 billion, making it a small-cap company.
Does NVRO pay dividends?
No, Nevro Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBSGM
BioSig Technologies, Inc.
$6.10
Mkt Cap: $0.2B
CRGX
CARGO Therapeutics, Inc. Common Stock
$4.47
Mkt Cap: $0.2B
EYESW
Second Sight Medical Products Inc
$0.22
0INZY
Inozyme Pharma, Inc.
$4.00
Mkt Cap: $0.3B
LSB
LakeShore Biopharma Co., Ltd
$0.63
Mkt Cap: $0.0B
SISI
Shineco, Inc.
$0.38
Mkt Cap: $0.0B
SLRN
Acelyrin, Inc.
$2.27
Mkt Cap: $0.2B
SNDA
Sonida Senior Living, Inc.
$32.95
Mkt Cap: $0.6B
SPPI
Spectrum Pharmaceuticals, Inc.
$1.02
Mkt Cap: $0.2B
TCRT
Alaunos Therapeutics, Inc.
$3.56
Mkt Cap: $0.0B
Explore stocks similar to NVRO for comparison